The San Antonio Breast Cancer Symposium, held annually in the Texas city that is its namesake, attracts thousands of researchers, physicians, health professionals, patient advocates, and others who share the mission of advancing the battle against breast cancer. The symposium provides a critical opportunity for researchers to present their latest findings, learn about the work of other scientists, and share ideas for future studies.
This year's event, which ran from December 8 through 12, drew more than 7,000 attendees from nearly 100 countries and included more than 1,400 research presentations.
Researchers and physicians from the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute comprise a major contingent at each year's symposium.
Renowned Dana-Farber breast cancer experts shared their discoveries, innovations, and insights from their research and clinical practice with thousands of their fellow oncologists and researchers from around the world.
San Antonio Breast Cancer Symposium 2015 Dana-Farber Participants
Conjugate drug extends survival in patients with advanced HER2-positive breast cancer
December 11, 2015
Research by Ian Krop, MD, PhD, shows a 44% survival improvement for patients with metastatic, HER2-positive breast cancer who received the combination antibody/chemotherapy drug trastuzumab.
Myles Brown, MD, Director, Center for Functional Cancer Epigenetics, speaks on "Genomics to personalize therapy of metastatic breast cancers" and gives an update on basic science discoveries for a Year in Review panel. Dr. Brown also speaks on "Hacking the Hormone Code in ER+ Breast Cancer" as part of his Susan G. Komen® Brinker Award for Scientific Distinction. View press release honoring Dr. Brown's research.
Jay Harris, MD, Chair, Department of Radiation Oncology, gives a plenary lecture on "Critical Decision Making in Radiation Therapy for Breast Cancer in 2015."
Geoffrey Shapiro, MD, PhD, Director, Early Drug Development Center, speaks on "Beyond CDK 4/6: Targeting additional cell cycle and transcriptional CDKs in breast cancer."
Dr. Jennifer Ligibel, breast oncologist at the Susan F. Smith Center for Women's Cancers, discusses promising new treatments for younger HER2+ breast cancer patients.
Beth Overmoyer, MD, breast oncologist at the Susan F. Smith Center for Women’s Cancer's at Dana-Farber, discusses new research she is presenting at the 2014 San Antonio Breast Cancer Symposium on risk factors for Inflammatory Breast Cancer.
Dr. Harold Burstein, breast oncologist at the Susan F. Smith Center for Women’s Cancers at Dana-Farber Cancer Institute, shares the latest news from the 2014 San Antonio Breast Cancer Symposium.
Combination of carboplatin and chemotherapy improves outcomes for triple-negative breast cancer patientsIn a clinical trial involving women with triple-negative breast cancer, patients who received the drugs carboplatin and/or bevacizumab in combination with standard chemotherapy prior to surgery were more likely to have their tumors disappear entirely from the breast, according to data presented by investigators during the 2014 San Antonio Breast Cancer Symposium.
Blocking a pathway causing hormonal therapy resistance may benefit women with advanced ER/PR-positive breast cancerAdding a PI3K inhibitor to hormonal therapy for metastatic breast cancer may help overcome resistance to the hormonal therapy and delay disease progression, according to investigators from Dana-Farber Cancer Institute.
In this video, Dr. Eric Winer, Director of Breast Oncology at the Susan F. Smith Center for Women’s Cancers at Dana-Farber, discusses research to be shared by Dana-Farber physician-researchers and their colleagues at the 2014 Breast Cancer Symposium.
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free: